Effects of the mixed mu/kappa opioid nalbuphine on cocaine-induced changes in subjective and cardiovascular responses in men

Neuropsychopharmacology

Volumn 30, Issue 3, 2005, Pages 618-632

  Mello, Nancy K ^a   Mendelson, Jack H ^a   Sholar, Michelle B ^a   Jaszyna Gasior, Maria ^a   Goletiani, Nathalie ^a   Siegel, Arthur J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cardiovascular measures; Cocaine; Cocaine + nalbuphine; Cocaine abuse; Nalbuphine; Subjective effects

Indexed keywords

COCAINE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR; NALBUPHINE; PLACEBO;

ADDICTION RESEARCH CENTER INVENTORY SCORE; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CLINICAL TRIAL; COCAINE DEPENDENCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MIXTURE; DRUG SAFETY; DRUG SELF ADMINISTRATION; EUPHORIA; HEART RATE; HUMAN; LOCOMOTION; MALE; PRIORITY JOURNAL; RATING SCALE; RHESUS MONKEY; SEDATION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; VISUAL ANALOG SCALE; VOMITING;

ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; BLOOD PRESSURE; COCAINE; DIASTOLE; DRUG INTERACTIONS; HEART RATE; HUMANS; MALE; NALBUPHINE; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; SYSTOLE;

EID: 13944260175     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300631     Document Type: Article

References (69)

1. Abreu ME, Bigelow GE, Fleisher L, Walsh SL (2001). Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacology 154: 76-84.
2. Abusada GM, Abukhalaf IK, Alford DD, Vinzon-Bautista I, Pramanik AK, Ansari NA et al (1993). Solid-phase extraction and GC/MS quantitation of cocaine, ecgonine methyl ester, benzoylecgonine, and cocaethylene from meconium, whole blood, and plasma. J Anal Toxicol 17: 353-358.
3. Archer S, Glick SD, Bidlack J (1996). Cyclazocine revisited. Neurochem Res 21: 1369-1373.
4. Bergman J, France CP, Holzman SG, Katz JL, Koek W, Stephens DN (2000). Agonist efficacy, drug dependence, and medications development: preclinical evaluation of opioid, dopaminergic, and GABA-ergic ligands. Psychopharmacology 153: 67-84.
5. Bowen CA, Negus SS, Zong R, Neumeyer JL, Bidlack JM, Mello NK (2003). Effects of mixed-action kappa-mu opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys. Neuropsychopharmacology 28: 1125-1139.
6. Caine SB, Negus SS, Mello NK (2000). Effects of dopamine D1-like and D2-like agonists on cocaine self-administration in rhesus monkeys: rapid assessment of cocaine dose-effect functions. Psychopharmacology 148: 41-51.
7. Carroll FI, Howell LL, Kuhar MJ (1999). Pharmacotherapies for treatment of cocaine abuse, preclinical aspects. J Med Chem 42: 2721-2736.
8. Crawford CA, McDougall SA, Bolanos CA, Hall S, Berger SP (1995). The effects of the kappa agonist U-50,488 on cocaine-induced conditioned and unconditioned behaviors and Fos immuoreactivity. Psychopharmacology 120: 392-399.
9. De Souza EB, Schmidt WK, Kuhar MJ (1988). Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic. J Pharmacol Exp Ther 244: 391-402.
10. Devine DP, Leone P, Pocock D, Wise RA (1993). Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. J Pharmacol Exp Ther 266: 1236-1246.
11. Di Chiara G, Imperato A (1988). Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 244: 1067-1080.
12. Evans SM, Cone EJ, Henningfield JE (1996). Arterial and venous cocaine plasma concentrations in humans: relationship to route of administration, cardiovascular effects and subjective effects. J Pharmacol Exp Ther 279: 1345-1356.
13. Foltin RW, Christiansen I, Levin FR, Fischman MW (1995). Effects of single and multiple intravenous cocaine injections in humans maintained on methadone. J Pharmacol Exp Ther 275: 38-47.
14. Foltin RW, Fischman MW (1991). Assessment of abuse liability of stimulant drugs in humans: a methodological survey. Drug Alcohol Depend 28: 3-48.
15. Foltin RW, Fischman MW (1992). The cardiovascular and subjective effects of intravenous cocaine and morphine combinations in humans. J Pharmacol Exp Ther 261: 623-632.
16. Glick SD, Maisonneuve IM, Raucci J, Archer S (1995). Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res 681: 147-152.
17. Hemby SE, Co C, Dworkin SI, Smith JE (1999). Synergistic elevations in nucleus accumbens extracellular dopamine concentrations during self-administration of cocaine/heroin combinations (Speedball) in rats. J Pharmacol Exp Ther 288: 274-280.
18. Hemby SE, Smith JE, Dworkin SI (1996). The effects of eticlopride and naltrexone on responding maintained by food, cocaine, heroin and cocaine/heroin combinations in rats. J Pharmacol Exp Ther 277: 1247-1258.
19. Howell LL, Wilcox KM (2001). The dopamine transporter and cocaine medication development: drug self-admnistration in nonhuman primates. J Pharmacol Exp Ther 298: 1-6.
20. Jaffe JH, Martin WR (1990). Opioid analgesics and antagonists. In: Gilman AG, Rall TW, Nies AS, Taylor P (eds). The Pharmacological Basis of Therapeutics. Pergamon Press: New York, pp 485-521.
21. Kaufman MJ, Levin JM, Ross MH, Lange N, Rose SL, Kukes TJ et al (1998). Cocaine-induced cerebral vasoconstriction detected in humans with magnetic resonance angiography. JAMA 279: 376-380.
22. Kuhar MJ, Ritz MC, Boja JW (1991). The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 14: 299-302.
23. Kuzmin AV, Semenova S, Gerrits MAFM, Zvartau EE, Van Ree JM (1997). Kappa-opioid receptor agonist U50,488 H modulates cocaine and morphine self-administration in drug-naive rats and mice. Eur J Pharmacol 321: 265-271.
24. Maisonneuve IM, Archer S, Glick SD (1994). U50,488 a K opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci Lett 181: 57-60.
25. Mansour A, Fox CA, Meng F, Akil H, Watson SJ (1994). Kappa 1 receptor mRNA distribution in the rat CNS: comparison to kappa receptor binding and prodynorphin mRNA. Mol Cell Neurosci 5: 124-144.
26. Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971). Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12: 245-258.
27. Mello NK, Kamien JB, Lukas SE, Drieze J, Mendelson JH (1993). The effects of nalbuphine and butorphanol treatment on cocaine and food self-administration by rhesus monkey. Neuropsychopharmacology 8: 45-55.
28. Mello NK, Negus SS (1996). Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology 14: 375-424.
29. Mello NK, Negus SS (1998a). The effects of buprenorphine on self-administration of cocaine and heroin 'Speedball' combinations and heroin alone by rhesus monkeys. J Pharmacol Exp Ther 285: 444-456.
30. Mello NK, Negus SS (1998b). Effects of kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. J Pharmacol Exp Ther 286: 812-824.
31. Mello NK, Negus SS (2000). Interactions between kappa opioid agonists and cocaine: Preclinical studies. In: Glick SD and Maisonneuve IM (eds). The Archer Conference on Drug Abuse: New Medications. New York Academy of Sciences: New York, pp 104-132.
32. Mello NK, Negus SS, Lukas SE, Mendelson JH, Sholar JW, Drieze J (1995). A primate model of polydrug abuse: Cocaine and heroin combinations. J Pharmacol Exp Ther 274: 1325-1337.
33. Mendelson JH, Mello NK (1996). Drug Therapy: Management of cocaine abuse and dependence. N Engl J Med 334: 965-972.
34. Mendelson JH, Mello NK (2004). Cocaine and other commonly abused drugs. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL and Jameson JL (eds). 16th Edition of Harrison's Principles of Internal Medicine. The McGraw-Hill Co.: New York, pp 2570-2573.
35. Mendelson JH, Mello NK, Sholar MB, Siegel AJ, Kaufman MJ, Levin JM et al (1999). Cocaine pharmacokinetics in men and in women during the follicular and luteal phase of the menstrual cycle. Neuropsychopharmacology 21: 294-303.
36. Mendelson JH, Mello NK, Sholar MB, Siegel AJ, Mutschler N, Halpern J (2002). Temporal concordance of cocaine effects on mood states and neuroendocrine hormones. Psychoneuroendocrinology 27: 71-82.
37. Mendelson JH, Sholar M, Mello NK, Teoh SK, Sholar JW (1998). Cocaine tolerance: Behavioral, cardiovascular, and neuroendocrine function in men. Neuropsychopharmacology 18: 263-271.
38. Mendelson JH, Sholar M, Siegel AJ, Mello NK (2001). Effects of cocaine on luteinizing hormone in women during the follicular and luteal phases of the menstrual cycle and in men. J Pharmacol Exp Ther 296: 972-979.
39. Meng F, Xie GX, Thompson RC, Mansour A, Goldstein A, Watson SJ et al (1993). Cloning and pharmacological characterization of a rat kappa opioid receptor. Proc Natl Acad Sci USA 90: 9954-9958.
40. Negus SS, Gatch MB, Mello NK (1998). Discriminative stimulus effects of a cocaine/heroin 'speedball' combination in rhesus monkeys. J Pharmacol Exp Ther 285: 1123-1136.
41. Negus SS, Mello NK (1999). Effects of kappa opioid agonists on the discriminative stimulus effects of cocaine in rhesus monkeys. Exp Clin Psychopharmacol 7: 307-317.
42. Negus SS, Mello NK (2002). Effects of μ-opioid agonists on cocaine- and food-maintained responding and cocaine discrimination in rhesus monkeys: role of μ-agonist efficacy. J Pharmacol Exp Ther 300: 111-1121.
43. Negus SS, Mello NK, Portoghese PS, Lin C-E (1997). Effects of kappa opioids on cocaine self-administration by rhesus monkeys. J Pharmacol Exp Ther 282: 44-55.
44. Novick DM, Haverkos HW, Teller DW (1997). The medically ill substance abuser. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG (eds). Substance Abuse A Comprehensive Textbook, 3rd edn. Williams & Wilkins: Baltimore, MD. pp 534-550.
45. PDR (ed) (2003). Physicians Desk Reference, 57th edn. Thomson PDR: Montvale, NJ.
46. Pfeiffer A, Branti V, Herz A, Emrich HM (1986). Psychotomimesis mediated by k opiate receptors. Science 233: 774-776.
47. Platt DM, Rowlett JK, Spealman RD (2002). Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development. Psychopharmacology (Berl) 163: 265-282.
48. Preston KL, Bigelow GE (2000). Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination. J Pharmacol Exp Ther 295: 114-124.
49. Preston KL, Bigelow GE, Liebson IA (1989). Antagonist effects of nalbuphine in opioid-dependent humans. J Pharmacol Exp Ther 248: 929-937.
50. Preston KL, Jasinski DR (1991). Abuse liability studies of opioid agonist-antagonists in humans. Drug Alcohol Depend 28: 49-82.
51. Preston KL, Sullivan JT, Strain EC, Bigelow GE (1996). Enhancement of cocaine's abuse liability in methadone maintenance patients. Psychopharmacology 123: 15-25.
52. Reece PA, Sedman AJ, Rose S, Wright DS, Dawkins R, Rajagopalan R (1994). Diuretic effects, pharmacokinetics, and safety of a new centrally acting kappa-opioid agonist (CI-977) in humans. J Clin Pharmacol 34: 1126-1132.
53. Rowlett JK, Wilcox KM, Woolverton WL (1998). Self-administration of cocaine-heroin combinations by rhesus monkeys: antagonism by naltrexone. J Pharm Exp Ther 286: 61-69.
54. Rowlett JK, Woolverton WL (1997). Self-administration of cocaine and heroin combinations by rhesus monkeys responding under a progressive-ratio schedule. Psychopharmacology (Berl) 133: 363-371.
55. SAMHSA (2000). Substance Abuse and Mental Health Services Administration. Major Drugs of Abuse from the 2000 Drug Abuse Warning Network Report. US Department of Health and Human Services: Rockville, MD.
56. Schenk S, Partridge B, Shippenberg TS (2001). Effects of the kappa-opioid receptor agonist, U69,593, on the development of sensitization and on the maintenance of cocaine self-administration. Neuropsychopharmacology 24: 441-450.
57. Schmidt WK, Tam SW, Shotzberger GS, Smith Jr DH, Clark R, Vernier VG (1985). Nalbuphine. In: Schuster CR, Harris LS (eds). Mixed Agonist-Antagonist Analgesics, Drug Alcohol Depend. Elsevier Science Publishers: New York, pp 339-362.
58. Shippenberg TS, Chefer VI, Zapata A, Heidbreder CA (2001). Modulation of the behavioral and neurochemical effects of psychostimulants by κ-opioid receptor systems. In: Quinones-Jenab V (ed). The Biological Basis of Cocaine Addiction. Annals of New York Academy of Sciences: New York, pp 50-73.
59. Sholar MB, Mendelson JH, Mello NK, Siegel AJ, Kaufman MJ, Levin JM et al (1998). Concurrent pharmacokinetic analysis of plasma cocaine and adrenocorticotropic hormone in men. J Clin Endocrinol Metab 83: 966-968.
60. Spangler R, Zhou Y, Maggos CE, Zlobin A, Ho A, Kreek MJ (1996). Dopamine antagonist and 'binge' cocaine effects on rat opioid and dopamine transporter mRNAs. Neuroreport 7: 2196-2200.
61. Spealman RD, Bergman J (1994). Opioid modulation of the discriminative stimulus effects of cocaine: comparison of μ, κ and ∂ agonists in squirrel monkeys discriminating low doses of cocaine. Behav Pharmacol 5: 21-31.
62. 2 dopamine receptors in the behavioral effects of cocaine. Neurochem Int 20: 147S-152S.
63. Strain EC, Stitzer ML, Liebson IA, Bigelow GE (1994). Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology 116: 401-406.
64. Svingos AL, Colago EE, Pickel VM (1999). Cellular sites for dynorphin activation of kappa-opioid receptors in the rat nucleus accumbens shell. J Neurosci 19: 1804-1813.
65. Walsh SL, Geter-Douglas B, Strain EC, Bigelow GE (2001a). Enadoline and butorphanol: evaluation of κ-agonists on cocaine pharmacodynamics and cocaine self-administration in humans. J Pharmacol Exp Ther 299: 147-158.
66. Walsh SL, Strain EC, Abreu ME, Bigelow GE (2001b). Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology 157: 151-162.
67. Walsh SL, Sullivan JT, Preston KL, Garner J (1996). The effects of naltrexone on response to i.v. cocaine, hydromorphone and their combination in humans. J Pharmacol Exp Ther 279: 524-538.
68. Yuferov V, Zhou Y, LaForge KS, Spangler R, Ho A, Kreek MJ (2001). Evaluation of guinea pig brain preprodynorphin mRNA expression and hypothalamic-pituitary-adrenal axis activity by 'binge' pattern cocaine administration. Brain Res Bull 55: 65-70.
69. Zacny JP, Conley K, Galinkin J (1997). Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers. J Pharmacol Exp Ther 282: 1187-1197.